Menu
Search
|

Menu

Close
X

Acceleron Pharma Inc XLRN.OQ (NASDAQ Stock Exchange Global Market)

42.55 USD
+0.58 (+1.38%)
As of Feb 20
chart
Previous Close 41.97
Open 41.72
Volume 111,057
3m Avg Volume 119,952
Today’s High 43.20
Today’s Low 41.72
52 Week High 46.51
52 Week Low 24.48
Shares Outstanding (mil) 44.04
Market Capitalization (mil) 1,680.20
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.14 Mean rating from 14 analysts

KEY STATS

Revenue (mm, USD)
FY17
7
FY16
28
FY15
18
EPS (USD)
FY17
-1.430
FY16
-1.521
FY15
-1.903
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
127.91
5.77
Price to Book (MRQ)
vs sector
7.82
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-41.85
14.43
Return on Equity (TTM)
vs sector
-44.00
16.13

EXECUTIVE LEADERSHIP

Francois Nader
Independent Chairman of the Board, Since 2015
Salary: --
Bonus: --
Habib Dable
President, Chief Executive Officer, Director, Since 2016
Salary: $45,833.00
Bonus: $350,000.00
Kevin McLaughlin
Chief Financial Officer, Senior Vice President, Treasurer, Since 2010
Salary: $368,113.00
Bonus: --
Matthew Sherman
Executive Vice President and Chief Medical Officer, Since 2015
Salary: $427,450.00
Bonus: --
Ravindra Kumar
Senior Vice President, Chief Scientific Officer, Since 2016
Salary: $355,000.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

128 Sidney St
CAMBRIDGE   MA   02139-4239

Phone: +1617.6499200

Acceleron Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily. It has four internally discovered therapeutic candidates that are in clinical trials, which include luspatercept, sotatercept, dalantercept and ACE-083. It offers a platform technology, IntelliTrap. It is also evaluating ACE-1332, a selective TGF-beta antagonist, for treatment of disorders with a fibrotic component, and additional molecules from its IntelliTrap platform for undisclosed therapeutic areas. Dalantercept is designed to treat cancers by inhibiting blood vessel formation by inhibiting signaling through the ALK1 receptor. ACE-083 is designed to promote muscle growth and function in specific, targeted muscles.

SPONSORED STORIES